ArticleBMC veterinary research2026
A novel Streptomyces zaomyceticus metabolite exhibits antifungal activity against Candida albicans in African catfish.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional characterization and mechanistic basis of antifungal and plant growth-promoting traits ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infection, particularly that caused by Candida albicans, pose emerging challenges in aquaculture, leading to significant economic and health losses in cultured fishes. However, limited research has explored eco-friendly antifungal alternatives for Clarias gariepinus, a species of high commercial value and susceptibility to fungal pathogens. This study aimed to isolate and identify marine-derived Actinobacteria capable of producing potent antifungal compounds effective against C. albicans. An initial screening of 30 Actinobacteria isolates obtained from thirty marine samples collected from Marsa Alam, Egypt was conducted. Among these, Streptomyces zaomyceticus (PQ395286) was identified as a producer of lucidin (1,3-diethoxy-1,1,3,3-tetramethyl lucidin), a novel bioactive metabolite with strong antifungal activity. In vitro assays demonstrated that lucidin inhibited C. albicans (ATCC 10221) with a minimum inhibitory concentration (MIC) of 0.5 μg/mL as confirmed by scanning electron microscopy. To evaluate its in vivo efficacy, C. gariepinus were randomly divided into four groups (three replicates each, 10 fish per replicate). Group 1 served as the negative control (no infection or treatment); Group 2 received lucidin exposure at 100 μg/L through water administration; Group 3 was intraperitoneally infected with C. albicans (3.6 × 104 CFU/fish); and Group 4 was both infected and treated with lucidin. Lucidin treatment markedly alleviated infection-induced alterations in hepatorenal biomarkers, nonspecific immunity, and antioxidant status. It significantly enhanced nitric oxide (NO) production, lysozyme (LYZ) activity, and overall antioxidant capacity. Histological observations confirmed that lucidin effectively restored the normal architecture of the liver, kidney, and spleen. Collectively, these findings highlight lucidin as a promising natural antifungal agent that can effectively mitigate C. albicans infection in C. gariepinus, thereby contributing to the development of sustainable antifungal strategies in aquaculture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.